

ASSIGNMENT OF INVENTION AND PATENT RIGHTS**Parties:**

- (1) **MCCARTHY, James** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (2) **LEGG, Sandrine** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (3) **LEWIS, Giles** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (4) **MITCHELL, Laura Sophie** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (5) **BARTON, Justin** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (6) **JENKINS, Emma** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (7) **MINTER, Ralph Raymond** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (8) **FINCH, Donna** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (9) **GALSON, Jacob Daniel** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (10) **OSBOURN, Jane Katherine** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (11) **DIAS DO NASCIMENTO, Jorge Norman** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (12) **KOLASINSKA-ZWIERZ, Pauline Maria** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom; and
- (13) **HAWTHORNE, William James** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;

The **'Inventors'**; and

- (14) **ALCHEMAB THERAPEUTICS LTD** incorporated and registered in England & Wales with company number 12156844 whose registered office is at East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom (the **'Assignee'**);

Together the **'parties'** or each a **'party'** as the context may indicate.

Whereas:

The Inventors are inventors of an invention entitled ANTI-UNC5C ANTIBODIES” (the ‘**Invention**’), which is the subject matter of the patent applications detailed in the schedule to this Assignment (the ‘**Patents**’).

IT IS AGREED as follows:

1. Assignment

In consideration of the sum of £1 (receipt and sufficiency of which the Inventors expressly acknowledge), each of the Inventors hereby assigns to the Assignee absolutely all of their right, title and interest in, to and arising from the Invention and the Patents, including (without limitation):

- (a) In respect of any and each application in the Patents:
 - (i) the right to claim priority from the Patents;
 - (ii) the right to file and prosecute national and regional applications in any country or territory in the world linked to the Patents, and the rights to all matter contained in such applications (the ‘**Regional Applications**’);
 - (iii) the right to file and prosecute divisional applications, continuations and continuations-in-part of all Regional Applications (the ‘**Divisional Applications**’); and
 - (iv) the absolute entitlement to any patents granted pursuant to all Regional Applications and Divisional Applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates; and
- (b) The right (in any relevant court of law, patent registry or other office) to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the Invention, the Patents and any patents granted on any of the applications filed as aforesaid in sub-clause (a), whether occurring before, on or after the date of this Assignment.

2. Further assurance

At the Assignee's expense, each of the Inventors will promptly execute and deliver such documents and perform such acts as may be required for the purpose of giving full effect to this Assignment.

3. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed will constitute a duplicate original, but all the counterparts will together constitute the one Assignment.

4. Governing law & jurisdiction

This Assignment is governed by the law of England and Wales and is subject to the non-exclusive jurisdiction of its courts.

This Assignment has been entered into on the final signature date below.

Signed by **James MCCARTHY**

DocuSigned by:

F2A1394C3445476...
Signature of Inventor

28-May-2024
Date: _____


Signed by **Sandrine LEGG**

DocuSigned by:

29BEEC6DECD0438...
Signature of Inventor

03-Jun-2024
Date: _____

Signed by **Giles LEWIS**

DocuSigned by:

F31A4B7F6EFC4C1...
Signature of Inventor

31-May-2024
Date: _____

Signed by **Laura Sophie MITCHELL**

DocuSigned by:

7BE59E4CB04E401...
Signature of Inventor

28-May-2024
Date: _____

Signed by **Justin BARTON**

DocuSigned by:

7433795E3A514A6
Signature of Inventor

28-May-2024
Date: _____

Signed by **Emma JENKINS**

DocuSigned by:

4D6B4BAA8DDE47C...
Signature of Inventor

28-May-2024
Date: _____

Signed by **Ralph Raymond MINTER**

DocuSigned by:

6EEA4CB063B346C...
Signature of Inventor

28-May-2024
Date: _____


Signed by **Donna FINCH**

DocuSigned by:

6DF7AD2E61FE4D6...
Signature of Inventor

28-May-2024
Date: _____

Signed by **Jacob Daniel GALSON**

DocuSigned by:

D64AA703F72A4D4...
Signature of Inventor

28-May-2024
Date: _____

Signed by **Jane Katherine OSBOURN**

DocuSigned by:

C89DC06A8ED044F...
Signature of Inventor

28-May-2024
Date: _____

Signed by **Jorge Norman DIAS DO NASCIMENTO**

DocuSigned by:

6FA408676C81484...
Signature of Inventor

28-May-2024
Date: _____

Signed by **Pauline Maria KOLASINSKA-ZWIERZ**

Signature of Inventor

Date: _____

Signed by **William James HAWTHORNE**

DocuSigned by:

E8870024FA09486...
Signature of Inventor

28-May-2024
Date: _____

Signed by Young Kwon
(print name), director or authorised representative,
for and on behalf of **ALCHEMAB THERAPEUTICS LTD**

DocuSigned by:

32F060DAEC5C477...
Signature of director or authorised representative

13-Jun-2024
Date: _____

Schedule: The Patents**Priority Applications**

Country	Priority application number	Filing date	Title
GB	2300277.7	9 January 2023	ANTI-UNC5C ANTIBODIES
GB	2317371.9	13 November 2023	ANTI-UNC5C ANTIBODIES
GB	2319255.2	15 December 2023	ANTI-UNC5C ANTIBODIES

Completion Applications

Country	PCT application number	Filing date	Title
WO	PCT/EP2024/050407	9 January 2024	ANTI-UNC5C ANTIBODIES
US	18/408509	9 January 2024	ANTI-UNC5C ANTIBODIES

ASSIGNMENT OF INVENTION AND PATENT RIGHTS**Parties:**

- (1) **MCCARTHY, James** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (2) **LEGG, Sandrine** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (3) **LEWIS, Giles** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (4) **MITCHELL, Laura Sophie** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (5) **BARTON, Justin** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (6) **JENKINS KNIGHT, Emma** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (7) **MINTER, Ralph Raymond** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (8) **FINCH, Donna** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (9) **GALSON, Jacob Daniel** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (10) **OSBOURN, Jane Katherine** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (11) **DIAS DO NASCIMENTO, Jorge Norman** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;
- (12) **KOLASINSKA-ZWIERZ, Paulina Maria** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom; and
- (13) **HAWTHORNE, William James** care of Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom;

The **'Inventors'**; and

- (14) **ALCHEMAB THERAPEUTICS LTD** incorporated and registered in England & Wales with company number 12156844 whose registered office is at East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom (the **'Assignee'**);

Together the **'parties'** or each a **'party'** as the context may indicate.

Whereas:

The Inventors are inventors of an invention entitled ANTI-UNC5C ANTIBODIES” (the ‘**Invention**’), which is the subject matter of the patent applications detailed in the schedule to this Assignment (the ‘**Patents**’).

IT IS AGREED as follows:

1. Assignment

In consideration of the sum of £1 (receipt and sufficiency of which the Inventors expressly acknowledge), each of the Inventors hereby assigns to the Assignee absolutely all of their right, title and interest in, to and arising from the Invention and the Patents, including (without limitation):

- (a) In respect of any and each application in the Patents:
 - (i) the right to claim priority from the Patents;
 - (ii) the right to file and prosecute national and regional applications in any country or territory in the world linked to the Patents, and the rights to all matter contained in such applications (the ‘**Regional Applications**’);
 - (iii) the right to file and prosecute divisional applications, continuations and continuations-in-part of all Regional Applications (the ‘**Divisional Applications**’); and
 - (iv) the absolute entitlement to any patents granted pursuant to all Regional Applications and Divisional Applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates; and
- (b) The right (in any relevant court of law, patent registry or other office) to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the Invention, the Patents and any patents granted on any of the applications filed as aforesaid in sub-clause (a), whether occurring before, on or after the date of this Assignment.

2. Further assurance

At the Assignee's expense, each of the Inventors will promptly execute and deliver such documents and perform such acts as may be required for the purpose of giving full effect to this Assignment.

3. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed will constitute a duplicate original, but all the counterparts will together constitute the one Assignment.

4. Governing law & jurisdiction

This Assignment is governed by the law of England and Wales and is subject to the non-exclusive jurisdiction of its courts.

This Assignment has been entered into on the final signature date below.

Signed by **James MCCARTHY**

Signature of Inventor

Date: _____

Signed by **Sandrine LEGG**

Signature of Inventor

Date: _____

Signed by **Giles LEWIS**

Signature of Inventor

Date: _____

Signed by **Laura Sophie MITCHELL**

Signature of Inventor

Date: _____

Signed by **Justin BARTON**

Signature of Inventor

Date: _____

Signed by **Emma JENKINS KNIGHT**

Signature of Inventor

Date: _____

Signed by **Ralph Raymond MINTER**

Signature of Inventor

Date: _____

Signed by **Donna FINCH**

Signature of Inventor

Date: _____

Signed by **Jacob Daniel GALSON**

Signature of Inventor

Date: _____

Signed by **Jane Katherine OSBOURN**

Signature of Inventor

Date: _____

Signed by **Jorge Norman DIAS DO NASCIMENTO**

Signature of Inventor

Date: _____

Signed by **Paulina Maria KOLASINSKA-ZWIERZ**

DocuSigned by:
Paulina Kolasinska-Zwierz
0B23D2004DC74C6...

Signature of Inventor

13-Jun-2024
Date: _____

Signed by **William James HAWTHORNE**

Signature of Inventor

Date: _____

Signed by Young Kwon
(print name), director or authorised representative,
for and on behalf of **ALCHEMAB THERAPEUTICS LTD**

DocuSigned by:
Young Kwon
32F060DAEC5C477...

Signature of director or authorised representative

13-Jun-2024
Date: _____

Schedule: The Patents**Priority Applications**

Country	Priority application number	Filing date	Title
GB	2300277.7	9 January 2023	ANTI-UNC5C ANTIBODIES
GB	2317371.9	13 November 2023	ANTI-UNC5C ANTIBODIES
GB	2319255.2	15 December 2023	ANTI-UNC5C ANTIBODIES

Completion Applications

Country	PCT application number	Filing date	Title
WO	PCT/EP2024/050407	9 January 2024	ANTI-UNC5C ANTIBODIES
US	18/408509	9 January 2024	ANTI-UNC5C ANTIBODIES

DEED OF ASSIGNMENT OF INVENTION & PATENT RIGHTS

Parties:

- (1) **SIDOR, Michelle** care of Alchemab, Inc., Corporation Trust Center, 1209 Orange Street, Wilmington, County of New Castle, Delaware 19808, United States of America (the **'Inventor'**);
- (2) **ALCHEMAB, INC.** incorporated and registered in the state of Delaware, United States of America with company number 5693575 whose registered office is at Corporation Trust Center, 1209 Orange Street, Wilmington, County of New Castle, Delaware 19808, United States of America (the **'Assignor'**); and
- (3) **ALCHEMAB THERAPEUTICS LTD** incorporated and registered in the United Kingdom with company number 12156844 whose registered office is at East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom (the **'Assignee'**);

Together the **'parties'** or each a **'party'** as the context may indicate.

Whereas:

The Inventor is an inventor of inventions (the **'Inventions'**), which are the subject matter of patent applications (the **'Patents'**). The Inventions and the Patents are detailed in the schedule to this deed of assignment (the **'Assignment'**).

IT IS AGREED as follows:

1. Assignment

The Inventor and the Assignor hereby assign to the Assignee absolutely all of their right, title and interest in, to and arising from the Inventions and the Patents, including (without limitation):

- (a) In respect of any and each application in the Patents:
 - (i) the right to claim priority from the Patents;
 - (ii) the right to file and prosecute national and regional applications in any country or territory in the world linked to the Patents, and the rights to all matter contained in such applications (the **'Regional Applications'**);
 - (iii) the right to file and prosecute divisional applications, continuations and continuations-in-part of all Regional Applications, and the rights to all matter contained in such applications (the **'Divisional Applications'**); and
 - (iv) the absolute entitlement to any patents granted pursuant to all Regional Applications and Divisional Applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates; and

- (b) The right (in any relevant court of law, patent registry or other office) to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the Inventions, the Patents and any patents granted on any of the applications filed as aforesaid in sub-clause (a), whether occurring before, on or after the date of this Assignment.

2. Further assurance

At the Assignee's expense, the Inventor and the Assignor will promptly execute and deliver such documents and perform such acts as may be required for the purpose of giving full effect to this Assignment.

3. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed will constitute a duplicate original, but all the counterparts will together constitute the one Assignment.


4. Governing law & jurisdiction

This Assignment is governed by the law of England and Wales and is subject to the non-exclusive jurisdiction of its courts.

This Assignment has been executed and delivered as a deed and is entered into and takes effect on the final signature date below.

Executed and delivered as a deed by

Michelle SIDOR in the presence of:

DocuSigned by:

 104B1763E9E6406...

SIGNATURE OF WITNESS

NAME: Sifis Pediaditakis

ADDRESS: 25 Green street, APT 3, Brookline, MA, USA

OCCUPATION: Associate Director of Neuroscience

DATE: 13-Mar-2024

DocuSigned by:

 3C5E17AD71C443A...
 Signature of Michelle SIDOR

Date: 12-Mar-2024

Executed and delivered as a deed by

Young Kwon

(print name), director or authorised representative,
for and on behalf of **ALCHEMAB, INC.** in the
presence of:

DocuSigned by:

Becky Eretta

90FF1B36AAAD47F...

SIGNATURE OF WITNESS

NAME: Becky Eretta

ADDRESS: 13 Milton view, Hitchin, Herts, SG4 0QD

OCCUPATION: HR Director

DATE: 14-Mar-2024

DocuSigned by:

Young Kwon

32F060DAEC5C477...

Signature of director or authorised
representative

Date: 13-Mar-2024

Executed and delivered as a deed by

Young Kwon

(print name), director or authorised representative,
for and on behalf of **ALCHEMAB THERAPEUTICS
LTD** in the presence of:

DocuSigned by:

Becky Eretta

90FF1B36AAAD47F...

SIGNATURE OF WITNESS

NAME: Becky Eretta

ADDRESS: 13 Milton view, Hitchin Herts, SG4 0QD

OCCUPATION: HR Director

DATE: 14-Mar-2024

DocuSigned by:

Young Kwon

32F060DAEC5C477...

Signature of director or authorised
representative

Date: 13-Mar-2024

Schedule: The Inventions and Patents**Netrin-1 family**

Country	Application number	Filing date	Title (Invention)
US	63/598282	13 November 2023	THERAPEUTIC USES OF NETRIN-1
GB	2317716.5	20 November 2023	THERAPEUTIC USES OF NETRIN-1

Anti-CD33 family

Country	Application number	Filing date	Title (Invention)
GB	2304932.3	3 April 2023	ANTI-CD33 ANTIBODIES

Anti-PGDH family

Country	Application number	Filing date	Title (Invention)
GR	20230101061	20 December 2023	ANTI-PGDH ANTIBODIES
GB	2400120.8	4 January 2024	ANTI-PGDH ANTIBODIES

ANTI-UNC5C family

Country	Application number	Filing date	Title (Invention)
GB	2317371.9	13 November 2023	ANTI-UNC5C ANTIBODIES
GB	2319255.2	15 December 2023	ANTI-UNC5C ANTIBODIES
US	18/408509	9 January 2024	ANTI-UNC5C ANTIBODIES
WO	PCT/EP2024/050407	9 January 2024	ANTI-UNC5C ANTIBODIES

CONFIRMATORY PATENT ASSIGNMENT

This CONFIRMATORY PATENT ASSIGNMENT ("**Assignment**"), dated as of April 15, 2025 (the "**Effective Date**"), is entered into by and between Alchemab Therapeutics Limited, East Side, Office 1.02, Kings Cross, London N1C 4AX ("**Assignor**") and Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA ("**Assignee**"). Both Assignor and Assignee are collectively referred to herein as the "**Parties**."

WHEREAS, Assignor wishes to assign to Assignee, and Assignee wishes to acquire from Assignor, all of the Assignor's rights, title, and interest in and to the patents and/or patent applications listed in **Schedule A** attached hereto ("**Assigned Assets**"), including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by the Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor had this Assignment and sale to Assignee not been made.

NOW, THEREFORE, as required pursuant the License and Collaboration Agreement, dated as of April 15, 2025, by and between the Parties, for other good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby sells, assigns, transfers and sets over unto Assignee, its successors and assigns Assignor's entire right, title and interest in, to and under the Assigned Assets, including absolute entitlement to any and all rights associated with the Assigned Assets, such as registrations granted pursuant to any of the applications contained, as well as any unregistered rights, inventions, designs, trade secrets, and other IP with the scope of the Assigned Assets; related goodwill and know-how associated with the Assigned Assets; and the right to bring, make, oppose, defend, appeal proceedings, claim or actions and obtain relief in respect of any infringement, or any other cause of action arising from ownership of any of the Assigned Assets, whether occurring before, on, or after the date of the Assignment.

WHEREAS, the parties wish to ratify and confirm the above-stated assignment and transfer;

NOW, THEREFORE, Assignor assigns and transfers, effective April 15, 2025 any and all right, title, and interest Assignor owns or otherwise holds in and to the Assigned Assets. The Assignee hereby confirms that it accepts the assignment and transfer to it of the Assigned Assets.

Assignor hereby authorizes and empowers Assignee to invoke and claim for any Assigned Assets, the benefit of any rights to which Assignor might be entitled under


international law or under the laws of any particular country, such as, without limitation, the right of priority provided under the International Convention for the Protection of Industrial Property, as amended, and to invoke and claim such rights without further authorization from Assignor.

The parties agree that schedules specific to individual jurisdictions for the Assigned Assets may be substituted for the attached Schedule for recordation purposes.

This Assignment and all terms hereof shall be binding upon and inure to the benefit of the parties and their respective heirs, personal representatives, successors, and assigns.

IN WITNESS WHEREOF, the Parties hereto have caused this Confirmatory Patent Assignment to be executed as of the Effective Date.

Assignor:

By: 
Name: JANE OSBOURN
Title: CEO

Accepted by:
Eli Lilly and Company

By: 
Name: Ted J. Ebersole
Title: Vice President, Assistant General Patent Counsel, Eli Lilly and Company

Schedule A
("Assigned Assets")

Mewburn Ref	Applicants	Status	Jurisdiction Code	Application Number	Application Date	Title
008376212	Alchemab Therapeutics Ltd	Abandoned (priority claimed)	GB	2300277.7	09/01/2023	ANTI-UNC5C antibodies
008509374	Alchemab Therapeutics Ltd	Abandoned (priority claimed)	GB	2317371.9	13/11/2023	ANTI-UNC5C antibodies`
008523623	Alchemab Therapeutics Ltd	Abandoned (priority claimed)	GB	2319255.2	15/12/2023	ANTI-UNC5C antibodies
008541344	Alchemab Therapeutics Ltd	Pending	WO	PCT/EP2024/050407	09/01/2024	ANTI-UNC5C antibodies
008554008	Alchemab Therapeutics Ltd	Pending	US	18/408,509	09/01/2024	ANTI-UNC5C antibodies
008648172	Alchemab Therapeutics Ltd	Pending	US	63/669271	10/07/2024	ANTI-UNC5C antibodies
008648180	Alchemab Therapeutics Ltd	Pending	US	63/705551	10/10/2024	ANTI-UNC5C antibodies

DEED OF ASSIGNMENT OF INVENTION & PATENT RIGHTS

Parties:

- (1) **PEDIADITAKIS, Iosif** care of Alchemab, Inc., Corporation Trust Center, 1209 Orange Street, Wilmington, County of New Castle, Delaware 19808, United States of America (the '**Inventor**');
- (2) **ALCHEMAB, INC.** incorporated and registered in the state of Delaware, United States of America with company number 5693575 whose registered office is at Corporation Trust Center, 1209 Orange Street, Wilmington, County of New Castle, Delaware 19808, United States of America (the '**Assignor**'); and
- (3) **ALCHEMAB THERAPEUTICS LTD** incorporated and registered in the United Kingdom with company number 12156844 whose registered office is at East Side Office 1.02, Kings Cross, London, N1C 4AX, United Kingdom (the '**Assignee**');;

Together the '**parties**' or each a '**party**' as the context may indicate.

Whereas:

The Inventor is an inventor of inventions (the '**Inventions**'), which are the subject matter of patent applications (the '**Patents**'). The Inventions and the Patents are detailed in the schedule to this deed of assignment (the '**Assignment**').

IT IS AGREED as follows:

1. Assignment

The Inventor and the Assignor hereby assign to the Assignee absolutely all of their right, title and interest in, to and arising from the Inventions and the Patents, including (without limitation):

- (a) In respect of any and each application in the Patents:
 - (i) the right to claim priority from the Patents;
 - (ii) the right to file and prosecute national and regional applications in any country or territory in the world linked to the Patents, and the rights to all matter contained in such applications (the '**Regional Applications**');;
 - (iii) the right to file and prosecute divisional applications, continuations and continuations-in-part of all Regional Applications, and the rights to all matter contained in such applications (the '**Divisional Applications**'); and
 - (iv) the absolute entitlement to any patents granted pursuant to all Regional Applications and Divisional Applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates; and

- (b) The right (in any relevant court of law, patent registry or other office) to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the Inventions, the Patents and any patents granted on any of the applications filed as aforesaid in sub-clause (a), whether occurring before, on or after the date of this Assignment.

2. Further assurance

At the Assignee's expense, the Inventor and the Assignor will promptly execute and deliver such documents and perform such acts as may be required for the purpose of giving full effect to this Assignment.

3. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed will constitute a duplicate original, but all the counterparts will together constitute the one Assignment.


4. Governing law & jurisdiction

This Assignment is governed by the law of England and Wales and is subject to the non-exclusive jurisdiction of its courts.

This Assignment has been executed and delivered as a deed and is entered into and takes effect on the final signature date below.

Executed and delivered as a deed by

Iosif PEDIADITAKIS in the presence of:

DocuSigned by:

 305E17AD71C443A...

DocuSigned by:

 104B1763E9F6406...
 Signature of Iosif PEDIADITAKIS

Date: 13-Mar-2024

SIGNATURE OF WITNESS

Michelle Sidor

NAME:

188 Mishawum Rd., Woburn, MA, USA, 01801

ADDRESS:

Director of Biology-Neuroscience

OCCUPATION:

DATE:

13-Mar-2024

Executed and delivered as a deed by

Young Kwon

(print name), director or authorised representative,
for and on behalf of **ALCHEMAB, INC.** in the
presence of:

DocuSigned by:

Becky Eretta

90FF1B36AAD47F...

DocuSigned by:

Young Kwon

32F060DAEC5C477...

Signature of director or authorised
representative

Date: 13-Mar-2024

SIGNATURE OF WITNESS

NAME: Becky Eretta

ADDRESS: 13 Milton view, Hitchin, Herts, SG4 0QD

OCCUPATION: HR Director

DATE: 14-Mar-2024

Executed and delivered as a deed by

Young Kwon

(print name), director or authorised representative,
for and on behalf of **ALCHEMAB THERAPEUTICS
LTD** in the presence of:

DocuSigned by:

Becky Eretta

90FF1B36AAD47F...

DocuSigned by:

Young Kwon

32F060DAEC5C477...

Signature of director or authorised
representative

Date: 13-Mar-2024

SIGNATURE OF WITNESS

NAME: Becky Eretta

ADDRESS: 13 Milton View, Hitchin, Herts, SG4 0QD

OCCUPATION: HR Director

DATE: 14-Mar-2024

Schedule: The Inventions and Patents**Netrin-1 family**

Country	Application number	Filing date	Title (Invention)
US	63/598282	13 November 2023	THERAPEUTIC USES OF NETRIN-1
GB	2317716.5	20 November 2023	THERAPEUTIC USES OF NETRIN-1

Anti-PGDH family

Country	Application number	Filing date	Title (Invention)
GR	20230101061	20 December 2023	ANTI-PGDH ANTIBODIES
GB	2400120.8	4 January 2024	ANTI-PGDH ANTIBODIES

ANTI-UNC5C family

Country	Application number	Filing date	Title (Invention)
GB	2317371.9	13 November 2023	ANTI-UNC5C ANTIBODIES
GB	2319255.2	15 December 2023	ANTI-UNC5C ANTIBODIES
US	18/408509	9 January 2024	ANTI-UNC5C ANTIBODIES
WO	PCT/EP2024/050407	9 January 2024	ANTI-UNC5C ANTIBODIES